Interleukin 8 in plasma is an efficacy marker for advanced non-small cell lung cancer treated with hypofractionated radiotherapy and PD-1 blockade
Pengyuan Kang(Southwest Medical University), Qing Yuan(Southwest Medical University), Dan Liu(General Hospital of Shenyang Military Region), Yingchun Ye(Wuhan University), Lin Li(Shanghai Jiao Tong University), Yunfei Li(Affiliated Hospital of Southwest Medical University), Sheng Lin(Guangzhou Medical University), Qin Jiang(Pfizer (United States)), Xiyuan Guo(Southwest Medical University)
Cited by 10
Related Papers
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
|Nature|2020|849
New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis
|Redox Biology|2018|753
Electrically pumped waveguide lasing from ZnO nanowires
|Nature Nanotechnology|2011|595